SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
CAMBRIDGE, Mass., March 29, 2017 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 9:20 a.m. ET in New York City.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days.
About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline includes GEN-003, a novel T cell-enabled immunotherapy for genital herpes currently in Phase 2 clinical development, and earlier-stage investments in immuno-oncology. For more information, please visit the company's website at www.genocea.com.
For media: Jennifer LaVin O: 617-715-6687 [email protected] For investors: Jonathan Poole O: 617-876-8191 [email protected]
